Evelo Biosciences Provides Clinical Updates
April 26, 2023 07:30 ET
|
Evelo Biosciences, Inc.
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV...
Atopic Dermatitis Drugs Market Predicted to Garner USD 24.5 Bn by 2032, At CAGR 9.1% | Market.us Report
April 24, 2023 20:57 ET
|
Market.Us
New York, April 24, 2023 (GLOBE NEWSWIRE) -- The atopic dermatitis drugs market size is projected to surpass around USD 24.5 billion by 2032 from USD 10.5 billion in 2022 and it is poised to reach a...
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
March 18, 2023 07:00 ET
|
Arcutis Biotherapeutics, Inc.
New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15%Rapid and significant improvements were...
Global Atopic Dermatitis Market Size To Grow USD 28.70 Billion by 2030 | CAGR of 10.5%
March 16, 2023 05:30 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , March 16, 2023 (GLOBE NEWSWIRE) -- The Global Atopic Dermatitis Market Size to grow from USD 15.20 Billion in 2021 to USD 28.70 Billion by 2030, at a Compound Annual Growth...
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
March 09, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis...
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
January 09, 2023 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that in a...
Insights on the Canine Atopic Dermatitis Global Market to 2027 - Increasing Occurrence of CAD in Domesticated Dogs Drives Growth
January 06, 2023 06:58 ET
|
Research and Markets
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Canine Atopic Dermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
December 05, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Atopic...
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
November 15, 2022 16:01 ET
|
Evelo Biosciences, Inc.
Peer-reviewed article explains the immunology of the small intestinal axisCompany to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 ...
CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
November 15, 2022 11:10 ET
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpointsFor the primary endpoint, 32.0% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success...